{"cluster": 20, "subcluster": 78, "abstract_summ": "Focusing on IgG antibodies, we demonstrate the performance of two ELISA assays (Euroimmun SARS-CoV-2 IgG & Vircell COVID-19 ELISA IgG) in comparison to one lateral flow assay ((LFA) FaStep COVID-19 IgG/IgM Rapid Test Device) and two in-house developed assays (immunofluorescence assay (IFA) and plaque reduction neutralization test (PRNT)).Focusing on IgG antibodies, we demonstrate the performance of two ELISA assays (Euroimmun SARS\u2010CoV\u20102 IgG and Vircell COVID\u201019 ELISA IgG) in comparison to one lateral flow assay ((LFA) FaStep COVID\u201019 IgG/IgM Rapid Test Device) and two in\u2010house developed assays (immunofluorescence assay (IFA) and plaque reduction neutralization test (PRNT)).So far, there is limited data on how commercially available tests perform with real patient samples and if positive tested samples show neutralizing abilities.The evaluated tests (including IgG and rapid tests) provided positive results in all patients at or after the 11th day post onset of disease.So far, there is little data on how commercially available tests perform with real patient samples and if detected IgG antibodies provide protective immunity.", "title_summ": "Clinical performance of SARS-CoV-2 IgG antibody tests and potential protective immunityComparison of SARS-CoV-2 serological tests with different antigen targetsClinical performance of different SARS\u2010CoV\u20102 IgG antibody testsPerformance of SARS-CoV-2 antibody assays in different stages of the infection: Comparison of commercial ELISA and rapid tests.Evaluating the serological status of COVID-19 patients using an indirect immunofluorescent assay, France.", "title_abstract_phrases": "Focusing on IgG antibodies, we demonstrate the performance of two ELISA assays (Euroimmun SARS-CoV-2 IgG & Vircell COVID-19 ELISA IgG) in comparison to one lateral flow assay ((LFA) FaStep COVID-19 IgG/IgM Rapid Test Device) and two in-house developed assays (immunofluorescence assay (IFA) and plaque reduction neutralization test (PRNT)).Focusing on IgG antibodies, we demonstrate the performance of two ELISA assays (Euroimmun SARS\u2010CoV\u20102 IgG and Vircell COVID\u201019 ELISA IgG) in comparison to one lateral flow assay ((LFA) FaStep COVID\u201019 IgG/IgM Rapid Test Device) and two in\u2010house developed assays (immunofluorescence assay (IFA) and plaque reduction neutralization test (PRNT)).So far, there is little data on how commercially available tests perform with real patient samples and if detected IgG antibodies provide protective immunity.So far, there is limited data on how commercially available tests perform with real patient samples and if positive tested samples show neutralizing abilities.We comparatively assessed sensitivities and specificities of four commercial ELISAs and two rapid tests in 77 patients with PCR confirmed SARS-CoV-2 infection, grouped by intervals since symptom onset."}